Liraglutide (Victoza): The first once-daily incretin mimetic injection for type-2 diabetes

P and T

Volumn 35, Issue 9, 2010, Pages

  Jackson, Sylvia H ^a   Martin, Tonya S ^a   Jones, Jocelyn D ^b   Seal, David ^a   Emanuel, Frank ^b  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TETRAHYDROLIPSTATIN;

AREA UNDER THE CURVE; BODY WEIGHT; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; RECOMMENDED DRUG DOSE; REVIEW; STOMACH EMPTYING; THYROID TUMOR; VOMITING; WEIGHT REDUCTION;

EID: 77957133420     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Centers for Disease Control and Prevention (CDC). National Diabetes Fact Sheet: General information and national estimates on diabetes in the United States, 2007. Available at: www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed March 18, 2010.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes, estimates for the year 2000, and projections for 2030. Diabetes Care 2004;27:1047-1053.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-853.
4. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes.Action to Control Cardiovascular Risk in Diabetes [ACCORD] Study Group. N Engl J Med 2008;353:2545-2559.
5. Duckworth W, Abraira C, Moritz T, et al., the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009:360:129-139.
6. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: The National Health and Nutrition Examination Survey. Diabetes Care 2006;29:531-537.
7. America Diabetes Association. Position statement: Standards of Medical Care in Diabetes - 2010. Diabetes Care 2010;33(Suppl):S11-S61.
8. American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus. Endocr Pract 2007:13(Supp1):S3-S66.
9. Amylin and Lilly announce FDA approval of Byetta (Exenatide) injection, April 29, 2005. Available at: www2.prnewswire.com. Accessed May 3, 2010.
10. Drucker DJ, Nauck M. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhib itors in type 2 diabetes. Lancet 2006;368:1696-1705. (Pubitemid 46048557)
11. Toft-Nielsen MB, Damhotl MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-3723. (Pubitemid 32755966)
12. Nauck M, Stockman F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-54.
13. Victoza (liraglutide), product information. Princeton, N.J.: Novo Nordisk, Inc.; January 2010.
14. Novo Nordisk receives U.S. approval for Victoza (liraglutide) for the treatment of type 2 diabetes, January 26, 2010. Available at: www.novonordisk.com/press/sea/sea.asp?sShowNewsItemGUID=7e58c0fd-2e96-4188-b201- a691ea2b4471&sShowLanguageCode=en-GB. Accessed March 10, 2010.
15. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety, and tolerability of NN2211, a new long-acting GLP-1 derivative in healthy men. Diabetologia 2002;45:195-202. (Pubitemid 34208381)
16. Russell-Jones D. Molecular, pharmacological, and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 2009;297:137-140.
17. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks, produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278.
18. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90.
19. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 MONO): Randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481.
20. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 2009;32:1224-1230.
21. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): A randomised controlled trial. Diabetologia 2009;52:2046-2055.
22. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
23. Buse JB, Sesti G, Schmidt W, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010;33:1300-1303.
24. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881-885. (Pubitemid 36929359)
25. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-520. (Pubitemid 28084232)
26. Raun K, Von-Voss P, Gotfredsen CF, et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56:8-15.
27. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic admini stration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001;50:2530-2539. (Pubitemid 33642771)
28. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-1616.
29. McKesson Corp., San Francisco. Available at www.mckesson.com. Accessed June 12, 2010.
30. Nathan DM, Buse JB, Davidson MD, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32;193-203.
31. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by the American Association of Clinical Endocrinologist/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algo rithm for glycemic control. Endocrinol Pract 2009;15:540-559.